Full Text View
Tabular View
No Study Results Posted
Related Studies
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
This study has been completed.
Study NCT01237873   Information provided by Novartis

First Received on October 29, 2010.   Last Updated on March 22, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Essential Hypertension
Additional conditions recognized in this trial
Hypertension
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
Ali/Amlo 150/2.5 mg
Additional drug interventions recognized in this trial
Amlodipine
More general drug interventions related to this trial
Antihypertensive Agents
Calcium Channel Blockers
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services